Efficacy and safety of ibandronate given by intravenous injection once every 3 months

de Groen, 1996, Esophagitis associated with the use of alendronate, N. Engl. J. Med., 335, 1016, 10.1056/NEJM199610033351403 Ettinger, 1998, Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis, Am. J. Manag. Care, 4, 1377 Graham, 1999, Alendronate gastric ulcers, Aliment. Pharmacol. Ther., 13, 515, 10.1046/j.1365-2036.1999.00488.x Lanza, 2000, Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women, Gastroenterology, 119, 631, 10.1053/gast.2000.16517 Lanza, 2000, Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women, Aliment. Pharmacol. Ther., 14, 1663, 10.1046/j.1365-2036.2000.00887.x Chesnut, 2003, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J. Bone Miner. Res. Bounameaux, 1983, Renal failure associated with intravenous diphosphonates, Lancet, 1, 471, 10.1016/S0140-6736(83)91465-4 Dumon, 1991, Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia, Bone Miner., 15, 257, 10.1016/0169-6009(91)90131-I Pecherstorfer, 1996, Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection, J. Bone Miner. Res., 11, 587, 10.1002/jbmr.5650110506 Neugebauer, 2001, Influence of peak ibandronic acid concentrations after 6 mg iv administration with shortened infusion time (15 and 30 minutes) on renal safety in man, Proc. Am. Soc. Clin. Oncol., 20, 122a Adami, 1996, Adverse effects of bisphosphonates. A comparative review, Drug Saf., 14, 158, 10.2165/00002018-199614030-00003 Recker, 2003, Clinical assessment of intravenous ibandronate injection once every 3 months in postmenopausal osteoporosis, Bone Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial, JAMA, 280, 2077, 10.1001/jama.280.24.2077 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, JAMA, 282, 1344, 10.1001/jama.282.14.1344 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, Osteoporos. Int., 11, 83, 10.1007/s001980050010 McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group, N. Engl. J. Med., 344, 333, 10.1056/NEJM200102013440503 Adami, 1999, Ibandronate, Drugs, 57, 109, 10.2165/00003495-199957010-00012 Lombas, 2000, Compliance with alendronate treatment in an osteoporosis clinic, J. Bone Miner. Res., 15, M406 Roldán, 2000, Short-term compliance to daily alendronate treatment in 1877 patients with osteoporosis. The ECMO study, J. Bone Miner. Res., 15, SU411 Thiébaud, 1997, Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis, Am. J. Med., 103, 298, 10.1016/S0002-9343(97)00249-0 Wasnich, 2000, Antifracture efficacy of antiresorptive agents are related to changes in bone density, J. Clin. Endocrinol. Metab., 85, 231, 10.1210/jc.85.1.231 Cummings, 2002, Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs, Am. J. Med., 112, 281, 10.1016/S0002-9343(01)01124-X Delmas, 2000, How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?, Bone, 27, 1, 10.1016/S8756-3282(00)00301-X Hochberg, 2002, Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents, J. Clin. Endocrinol. Metab., 87, 1586, 10.1210/jc.87.4.1586 Eastell, 2003, Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate, J. Bone Miner. Res., 18, 1051, 10.1359/jbmr.2003.18.6.1051 Schnitzer, 2000, Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group, Aging (Milano), 12, 1 Brown, 2002, The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis, Calcif. Tissue Int., 71, 103, 10.1007/s00223-002-2011-8 Christiansen, 2003, Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate, Osteoporos. Int., 14, 609, 10.1007/s00198-003-1409-0 Tankó, 2003, Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens, Bone, 32, 687, 10.1016/S8756-3282(03)00091-7